Market Place
Sourcing Support
Pfizer and Strata expand clinical partnership for cancer trial
14 Sep 2022 //
CLINICALTRIALSARENA
Amber Specialty Added to Pfizer’s Limited Distribution Network
03 Aug 2022 //
BUSINESSWIRE
Pfizer’s Lorviqua OKed as 1st-line therapy for ALK-positive NSCLC
19 May 2022 //
KOREABIOMED
EC Approves LORVIQUA as First-Line Treatment for ALK-Positive NSCLC
28 Jan 2022 //
BUSINESSWIRE
Pfizer’s Lorbrena gets US FDA approval to treat ALK-positive nsclc
04 Mar 2021 //
PHARMABIZ
Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval
04 Mar 2021 //
PMLIVE
Pfizer’s Lorbrena scores US priority review
04 Jan 2021 //
PHARMATIMES
LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer
28 Dec 2020 //
BUSINESSWIRE
LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer
28 Dec 2020 //
BUSINESSWIRE
LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer
28 Dec 2020 //
BUSINESSWIRE
LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer
28 Dec 2020 //
BUSINESSWIRE
CROWN TRIAL SUPPORTS LORLATINIB AS A FUTURE FIRST-LINE STANDARD TREATMENT
21 Sep 2020 //
ESMO
ESMO: Pfizer`s Lorbrena Makes Case To Claim ALK + Lung Cancer CROWN
20 Sep 2020 //
INFORMA
Pfizer`s Lorbrena bests Xalkori in PhIII readout — is it a potential successor?
06 Aug 2020 //
ENDPTS
Pfizer says Lorbrena met primary goal in lung cancer trial
06 Aug 2020 //
CLINICALTRIALSARENA
LORBRENA® (LORLATINIB) SIGNIFICANTLY IMPROVES PROGRESSION-FREE
05 Aug 2020 //
PRESS RELEASE
Pfizer`s Lorbrena makes play for earlier lung cancer use
05 Aug 2020 //
FIERCE PHARMA
LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival
04 Aug 2020 //
BUSINESSWIRE
NICE backs Roche’s Gazyvaro, Pfizer’s Lorviqua in new guidance
13 May 2020 //
PMLIVE
NICE final guidance backs Pfizer`s Lorviqua
13 May 2020 //
PHARMA TIMES
Pfizer to present clinical trials of 18 approved & investigational medicines
13 May 2020 //
PHARMABIZ
New Breakthrough Treatment for Patients with ALK-Positive Lung Cancer
27 Nov 2019 //
BIOSPECTRUM ASIA
Inivata collaborates with EORTC
29 Oct 2019 //
GLOBENEWSWIRE
Roche fields first approval for Rozlytrek
19 Jun 2019 //
ENDPTS
Pfizer, ‘never say never’ with big M&A, inks $11.4B Array cancer deal
18 Jun 2019 //
FIERCE PHARMA
Pfizer scores conditional EU approval in ALK-positive lung cancer with Lorviqua
08 May 2019 //
PHARMAFILE
Committee for medicinal products for human use (CHMP)
28 Jan 2019 //
EMA
U.S. FDA Approves LORBRENA® (lorlatinib) for met NSCLC
02 Nov 2018 //
BUSINESSWIRE
Pfizer racks up 3rd cancer drug OK, but can it replace regular price hikes?
02 Nov 2018 //
ENDPTS
Pfizer’s lorlatinib clears first hurdle to UK early access scheme
22 Aug 2018 //
PHARMA TIMES
